跳到正文
原文
STAT 主站· Andrew Joseph·· 25 天前AI 评分43

GSK癌症药物研发回归见效:六款获批药物及新适应症进展

STAT+: GSK sees its return to cancer start to pay off

AI 导读

GSK六款获批癌症药物近期取得新适应症进展,其靶向B7-H4的药物在ESMO展示首个全球研究数据,并宣布预计数周内将获批新肺癌药物。十年前退出癌症领域后,GSK通过持续研发实现业务复苏。

正文

The company could soon have its sixth approved cancer drug

A GSK ad at ESMO, touting its work targeting B7-H4.Andrew Joseph/STAT

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here. 

GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug. 

It’s a good run considering GSK was out of oncology a decade ago.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Europe Correspondent

    Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

来源:STAT 主站 · statnews.com